| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | NEUTRAL | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 182.24▼ | 182.70▼ | 182.74▼ | 176.84▲ | 166.91▲ |
| MA10 | 182.61▼ | 182.80▼ | 182.51▼ | 171.79▲ | 157.13▲ |
| MA20 | 182.84▼ | 182.48▼ | 181.11▲ | 163.28▲ | 146.43▲ |
| MA50 | 182.76▼ | 179.73▲ | 174.56▲ | 153.02▲ | 139.39▲ |
| MA100 | 182.52▼ | 173.90▲ | 167.70▲ | 143.85▲ | 174.07▲ |
| MA200 | 181.22▲ | 166.64▲ | 158.73▲ | 137.13▲ | 212.83▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.136▼ | -0.277▼ | -0.347▼ | 1.836▲ | 4.421▲ |
| RSI | 30.805▼ | 52.943▲ | 60.757▲ | 79.890▲ | 70.181▲ |
| STOCH | 5.949▼ | 47.015 | 69.962 | 84.497▲ | 85.056▲ |
| WILL %R | -97.651▼ | -62.748 | -26.596 | -9.688▲ | -6.021▲ |
| CCI | -129.335▼ | -60.367 | -10.984 | 149.318▲ | 209.154▲ |
|
Tuesday, November 25, 2025 04:53 AM
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...
|
|
Monday, November 24, 2025 07:29 AM
The major indexes were mixed Monday. Google popped amid Salesforce CEO Marc Benioff's praise for AI model Gemini 3. Novo Nordisk dived on Alzheimer's trial data.
|
|
Monday, November 24, 2025 07:16 AM
US biotech major Biogen and privately-held Dayra Therapeutics have announced a research collaboration to discover and develop oral macrocyclic peptides for priority targets in immunological conditions ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 26/11/25 | 181.96 | 183.93 | 180.76 | 181.94 | 1,482,900 |
| 25/11/25 | 177.07 | 182.97 | 176.09 | 181.96 | 2,344,500 |
| 24/11/25 | 177.65 | 185.17 | 175.57 | 176.82 | 4,153,600 |
| 21/11/25 | 168.54 | 176.02 | 167.42 | 175.30 | 2,268,000 |
| 20/11/25 | 168.15 | 170.91 | 165.75 | 168.18 | 1,905,600 |
| 19/11/25 | 168.83 | 168.90 | 165.79 | 167.93 | 1,765,500 |
| 18/11/25 | 164.40 | 170.78 | 163.00 | 168.83 | 2,257,400 |
| 17/11/25 | 167.00 | 167.97 | 163.50 | 164.68 | 2,244,600 |
| 14/11/25 | 164.72 | 169.00 | 163.00 | 167.55 | 2,620,400 |
| 13/11/25 | 161.57 | 167.87 | 161.20 | 164.73 | 2,992,400 |
|
|
||||
|
|
||||
|
|